540 Results for GLP-1 Pipeline Update
  • AMCP Annual 2024 - PDFs

    Medication Nonadherence Social Determinants of Health Risk Score: Development and Use 2024 AMCP Annual Posters Real-World First Year Cost-Effectiveness Assessment of Glucagon-Like Peptide-1...

  • Asembia

    Speaking Engagements Learn more Yuqian Liu and Camile Rabe & Tim O'Shea, Horizon Mission Impossible: How Integrated Medical & Pharmacy Benefits Can Improve Specialty Drug Management with Prime's...

  • Recapping Prime’s 21st annual Specialty Summit

    Marquee event showcased new Prime, our energy, ambition and transformative journey

    PA Sub-Categories: Specialty drugs Prime Article: Perspectives
  • Prime/MRx experts share clinical insights for migraine treatment

    Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs

    Prime Article: Stories
  • High-Cost Therapy Profile: June 2024

    Clinical deep dive Disease state overview Myelodysplastic syndromes (MDS) are classified as disorders in which there are abnormal (dysplastic) hematopoietic stem cells in the bone marrow, leading...

  • AMCP Nexus 2024 - PDFs

    Methodological Framework for Propensity Adjusted Benchmarks for Pharmacy Key Performance Indicators The purpose of the study was to create a methodological framework for using propensity score...

  • High Cost Therapy Profile: February 2025

    Clinical deep dive Disease state overview MacTel type 2 is a rare neurodegenerative disease that affects the macula, which processes central and color vision. It is a bilateral asymmetric...

  • HIGH COST THERAPY PROFILE: OCT 2024

    Publications High Cost Therapy Profile: October 2024 Eladocagene Exuparvovec October 15, 2024 References PTC Therapeutics announces FDA acceptance and Priority Review of the BLA for UpstazaTM. PTC...